Polyzois Makras, Socrates E. Papapoulos
Hypercalcaemia results from the failure of renal calcium excretion to compensate increased influx of calcium into the circulation from the intestine, the kidneys and the skeleton. Hypercalcaemia is a common metabolic abnormality of varying severity …
Konstantinos A. Toulis, Athanasios D. Anastasilakis, Stergios A. Polyzos, Polyzois Makras
Targeting osteoblast may be the means of effectively improving both bone quality and mass, thus offering an intriguing alternative in the treatment of osteoporosis. Aside from injectable parathyroid hormone (PTH) and its novel preparations, PTH-related peptide (PTHrP), calcilytics …
Mauro Doga, Stefania Bonadonna, Andrea Giustina
Chronic exposure to excessive concentrations of endogenous cortisol or to pharmacologic doses of glucocorticoids (GCs) causes multiple deleterious effects on body structure and function. Osteopenia, osteoporosis and bone fractures are well recognized consequences of excessive GC exposure, with fractures being a major cause of morbidity and mortality, particularly in the elderly. In particular, GCs have profound effects on bone metabolism, acting at many sites…
Marco Di Monaco, Carlotta Castiglioni, Rosa Tappero
OBJECTIVE: Hip-fracture patients with vitamin D deficiency can have either secondary hyperparathyroidism or normal levels of parathyroid hormone (PTH). We hypothesized that bone mineral density (BMD) could be lower in patients with high PTH levels than in those with normal levels of PTH, irrespectively of the severity of vitamin D depletion …
Salvatore Maria Corsello, Rosa Maria Paragliola, Pietro Locantore, Francesca Ingraudo, Maria Pia Ricciato, Carlo Antonio Rota, Paola Senes, Alfredo Pontecorvi
Zoledronic acid is a newly FDA-approved bisphosphonate for the treatment of hypercalcemia of malignancy. Although the safety and efficacy of this drug in treating hypercalcemia associated with hyperparathyroidism have not yet been established in clinically controlled trials, its off-label use is not uncommon …